Trial record 42 of 164 for:    curcumin

Curcumin Supplement in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02908152
Recruitment Status : Not yet recruiting
First Posted : September 20, 2016
Last Update Posted : September 20, 2016
Information provided by (Responsible Party):
Dr Azita Hekmatdoost, National Nutrition and Food Technology Institute

Brief Summary:
The purpose of this study is to investigate the effects of curcumin supplement on metabolic factors and hepatic fibrosis in nonalcoholic fatty liver patients with type 2 diabetes. Subjects will participate in 3 month, two group, randomized intervention, where one group (n=25) will take 1.5g/d curcumin and the other group (n=25) will take a placebo to compare differences in outcomes between the two groups.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Nonalcoholic Fatty Liver Dietary Supplement: curcumin Dietary Supplement: placebo Phase 2 Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of Curcumin Supplement on Metabolic Factors and Hepatic Fibrosis in Nonalcoholic Fatty Liver Patients With Type 2 Diabetes
Study Start Date : February 2017
Estimated Primary Completion Date : July 2017
Estimated Study Completion Date : October 2017

Arm Intervention/treatment
Active Comparator: curcumin
Dietary Supplement: curcumin

1500 mg

1 capsule / day for 12 weeks

Placebo Comparator: placebo Dietary Supplement: placebo

1500 mg

1 capsule / day for 12 weeks

Primary Outcome Measures :
  1. Hepatic steatosis [ Time Frame: [12 weeks] ]
    measured by CAP score using Fibroscan

Secondary Outcome Measures :
  1. Glucose [ Time Frame: [12 weeks] ]
  2. HBA1C [ Time Frame: [12 weeks] ]
  3. ALT [ Time Frame: [12 weeks] ]
  4. AST [ Time Frame: [12 weeks] ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient diagnosed with type 2 diabetes based on ADA definition or who only take oral antidiabetic drug;
  • CAP score >263.

Exclusion Criteria:

  • Taking any kind of antibiotics two weeks before recruitment;
  • History of alcohol consumption;
  • pregnancy or lactation;
  • Professional athletes;
  • Other liver disease (viral/etc);
  • High dose synthetic estrogens, methotrexate, amiodarone, steroids, chloroquine, immunosuppressive drugs;
  • A history of Cardiovascular disease;
  • Renal disease, Celiac disease, Cirrhosis;
  • History of Upper GI surgery;
  • A history of hypothyroidism or Cushing's syndrome;
  • History of drug dependence;
  • Body mass index (BMI) ≥35 kg/m2;
  • A restrictive diet or weight change ≥ 5 kg during the 3months prior to study;
  • Any change in treatment with oral hypoglycemic; anti hypertensive and antilipid agents during the study;
  • Use of weight loss medications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02908152

Iran, Islamic Republic of
Not yet recruiting
Tehran, Iran, Islamic Republic of
Sponsors and Collaborators
National Nutrition and Food Technology Institute

Responsible Party: Dr Azita Hekmatdoost, Principal Investigator, National Nutrition and Food Technology Institute Identifier: NCT02908152     History of Changes
Other Study ID Numbers: 467
First Posted: September 20, 2016    Key Record Dates
Last Update Posted: September 20, 2016
Last Verified: September 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Fatty Liver
Non-alcoholic Fatty Liver Disease
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Liver Diseases
Digestive System Diseases
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action